ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 702

Prediction Of Worsening Of Skin Fibrosis In Patients With Diffuse Systemic Sclerosis Using The EULAR Scleroderma Trials and Research (EUSTAR) Registry

Britta Maurer1, Nicole Graf2, Beat A. Michel3, Carola Metzig4, Vivian Lanius4, Dinesh Khanna5 and Oliver Distler1, 1Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2graf biostatistics, Winterthur, Switzerland, 3Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4Bayer Pharma AG, Berlin, Germany, 5University of Michigan Health System, Ann Arbor, MI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: clinical trials, skin and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

Background/Purpose: To identify predictive parameters for the progression of skin fibrosis in patients with diffuse cutaneous SSc (dcSSc) to enable 1) risk-stratification in clinical practice and 2) improved cohort enrichment in clinical trials with skin fibrosis as the primary endpoint.

Methods: An observational prospective study using the EUSTAR database was performed. Worsening of skin fibrosis was defined as increase in modified Rodnan skin score (mRSS) >5 points and ≥25% from the 1st to the 2nd visit. Inclusion criteria: dcSSc, ACR criteria fulfilled, mRSS≥7 at 1st visit, valid data for mRSS at 2ndvisit, period in between visits 12±2 months. In the univariate analysis, patients with progressive skin fibrosis were compared to non-progressive patients. Predictive markers with p<0.2 were included in the multivariate logistic regression analysis. For validation of the regression models, a second cohort with new patients was extracted from the EUSTAR database 11 months after the first data extraction.

Results:

Out of 637 patients fulfilling the inclusion criteria of the original cohort, 9.7% had progressive skin disease. Univariate analysis suggested the following prediction parameters: presence of joint synovitis (p=0.009), disease duration (p=0.023), mRSS at baseline (p=0.015), and the interaction between disease duration (≤15/>15 months, cut-off defined by ROC analysis) and sex (p=0.020) as well as the interaction between disease duration and CK elevation (p=0.047).

In the multivariate analysis, different prediction models with varying numbers and combinations of the predictors identified in the univariate analysis were compared. The model with the highest prediction success rate (n=8/18, 44.4%) showed an area under the ROC curve of 0.73 (95% CI=0.66-0.79, p<0.0001) with an overall accuracy of 89.9% (98.1% for no progression, 14.3% for progression) (Table1).

Tabl.1 Prediction model for skin progression in dcSSc

Predictors

p-value

OR

95%-CI

Joint synovitis

0.016

2.123

1.147-3.927

Female sex

0.143

0.541

0.238-1.230

Short disease duration* (≤15 months)

0.689

0.752

0.186-3.036

Female sex*short disease duration (≤15 months)

0.033

5.380

1.142-25.342

Low mRSS at baseline (≤22/51)

0.001

6.027

2.113-17.189

Other models with broader inclusion criteria revealed lower prediction success rates, but would simplify the recruiting process (e.g. prediction success rate 23.8% (n=20/84) for a model including low mRSS at baseline (≤22/51) and short disease duration (≤15 months)).

In the validation cohort, out of 188 patients, 6.5% had progressive skin disease. In the multivariate analysis, essentially the findings from the original cohort were confirmed, including the model in Table 1.

Conclusion: These data from a large cohort analysis including a 2nd verification cohort clearly have an important impact on the future clinical study design in SSc. The identified and validated criteria allow the enrichment for dcSSc patients with progressive active skin fibrosis by up to 4.5-fold.


Disclosure:

B. Maurer,
None;

N. Graf,
None;

B. A. Michel,
None;

C. Metzig,

Bayer Pharma AG,

3;

V. Lanius,

Bayer Pharma AG,

3;

D. Khanna,

BMS, Bayer, DIGNA, Actelion, Gilead, UT, Merck,

5;

O. Distler,

Actelion, Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, Roche/Genentech, medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4 D Science, Active Biotec, Sinoxa, Serodapharm,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prediction-of-worsening-of-skin-fibrosis-in-patients-with-diffuse-systemic-sclerosis-using-the-eular-scleroderma-trials-and-research-eustar-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology